(Q37378906)

20 August 2017

1 reference

title

Trastuzumab and doxorubicin-related cardiotoxicity and the cardioprotective role of exercise (English)

1 reference

20 August 2017

1 reference

Karen Y Wonders

1 reference

20 August 2017

Beverly S Reigle

series ordinal

1 reference

20 August 2017

publication date

27 January 2009

1 reference

Integrative Cancer Therapies

20 August 2017

published in

1 reference

20 August 2017

1 reference

20 August 2017

1 reference

20 August 2017

page(s)

17-21

1 reference

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

First--select the target: better choice of adjuvant treatments for breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Acute exercise protects against doxorubicin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Endurance training attenuates doxorubicin-induced cardiac oxidative damage in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Moderate endurance training prevents doxorubicin-induced in vivo mitochondriopathy and reduces the development of cardiac apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Exercise training attenuates acute doxorubicin-induced cardiac dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Signal transduction by receptors with tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Receptor protein-tyrosine kinases and their signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

New combinations with Herceptin in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

The molecular pharmacology of doxorubicin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Clinical cardiac tolerability of trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Adriamycin-induced heart failure: mechanism and modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Subcellular effects of adriamycin in the heart: a concise review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Cardiac toxicity of antineoplastic anthracyclines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

The neuregulin GGF2 attenuates free radical release from activated microglial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Physical Activity and Survival After Breast Cancer Diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

Randomized Controlled Trial of Exercise Training in Postmenopausal Breast Cancer Survivors: Cardiopulmonary and Quality of Life Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1534735408330717

21 January 2018

Identifiers

DOI

10.1177/1534735408330717

1 reference

20 August 2017

1 reference